A 6,9-hemiacetal) and EM523 (iV-demethyl-A^-ethyl-S^-anhydroerythromycin A 6,9-hemiacetal) have strong gastrointestinal motor stimulating (GMS) activity. When administered orally to dogs, these agents showed strong GMSactivity, but their plasma levels were very low and the metabolites which have been determined so far using the radio-labeled compounds show only weak GMSactivity. The findings suggested that unknownbioactive metabolites might be responsible for the GMSactivity.
Satoshi Omura
The Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo 108, Japan (Received for publication March 6, 1996) Twomotilides, EM574(N-demethyl-AMsopropyl-S^-anhydroerythromycin A 6,9-hemiacetal) and EM523 (iV-demethyl-A^-ethyl-S^-anhydroerythromycin A 6,9-hemiacetal) have strong gastrointestinal motor stimulating (GMS) activity. When administered orally to dogs, these agents showed strong GMSactivity, but their plasma levels were very low and the metabolites which have been determined so far using the radio-labeled compounds show only weak GMSactivity. The findings suggested that unknownbioactive metabolites might be responsible for the GMSactivity.
From the liver of dogs given EM574intravenously, two bioactive metabolites, EM574PI and P2, were isolated by solvent extraction and chromatography as detected by contractile activity. They both showed the same UVspectra as EM574and the molecular ion peaks at m/z 760 (MH+) and 602 (MH+-cladinose) in the FAB-MS.From 2D-NMRexperiments, the structures of EM574PI and P2 were unveiled to be the 15-and 14-hydroxyl derivatives of EM574, respectively. EM523PI and P2 were also isolated in the same procedure. In order to prepare these bioactive metabolites, EM574and EM523were converted enzymatically with dog liver homogenates in the presence of co-enzymes to give the corresponding PI and P2. The structures of the metabolites are shown in Recently, erythromycin (EM) has been reported to have GMS activities other than antibacterial activities.1~4) Firstly EMwas found to induce strong migratirig contractions, of which pattern was similar to that of naturally occuring interdigestive migrating contractions in dogs.1'2* As the action of EMwas very similar to that of the gastrointestinal hormone motilin, Itoh and Omura5'6) designated macrolides having motilin-like activities as "motilides." Later studies have provided evidence that EMis an agonist on motilin receptors.7~9) These evidences suggested that EMderivatives having stronger GMSactivity without antimicrobial activities are promising new prokinetic drugs. In the course of developing EMderivatives without antibacterial activity, EM574 (1) and EM523 (2) were AUG. 1996 found to have 248-and 18-fold stronger GMSactivity than EMA, respectively, whengiven intravenously. 10'1 1} Although both agents showed strong GMSactivity upon oral or intraduodenal administration, the plasma levels of the agents were very low. These findings suggested that bioactive metabolites might be responsible for the GMS activity. These observations prompted us to search for genuine "bioactive metabolites." The part of this paper has been orally reported. 14)
Results

Detection of Bioactive Metabolites in Dogs
First, to determine whether bioactive metabolites were produced after the administration of 1 and 2 to the dog, we examined the contractile activity in vitro using an isolated rabbit duodenum. A solution of 1 lactobionate (1L) was injected intravenously via a cephalic vein in the foreleg of the dog. After 0, 5, 15 and 30 minutes, a blood sample was removed from the vein.
One hour after injection, the dog was killed; blood was collected, and the liver was removed. In another experiment, urine and bile were collected via a cannula inserted into the bladder and bile duct, respectively, for 4hours after injection. The liver was homogenized in methanol and centrifuged.
The contractile activity of these samples was examined to check for the presence of bioactive metabolites. All the samples showed contractile activity, but they were too complex to analyze the quantity of the remaining 1. As a trial for preliminary purification, the bile was subjected to an adsorptive resin, Diaion HP-20, chromatography eluting with aqueous methanol. Contractile activity was detected in the fractions of 80% methanol in 5mM hydrochloric acid. The bile was partitioned between ethyl acetate and water (pH 3, 7 and 9). The portions showing contractile activity were the acidic aqueous layer and the organic layer at pH 9. These behavior of the active fraction indicated that the bioactive metabolites have a basic, fat-soluble nature, as in the case with the starting materials, 1 and 2. On the basis of these results, the other samples were partially purified using a series of HP-20 chromatography and solvent extraction at pH 9 to obtain the crude extracts as shown in Fig. 2 . The contractile activity was examined and compared with that of 1, and the extracts were subjected Table 1 . The activity observed in blood samples was mainly caused by the unchanged 1, and the bioactive metabolites existed in extracts from liver, bile and urine.
The crude extract from the bile was subjected to preparative HPLC(ODS), and all the fractions were examined for contractile activity. In HPLCusing 50% acetonitrile-0.02 M phosphate buffer (pH 4.0) as a mobile phase, the active fractions eluted within 3.5 minutes, and no activity was observed in the fractions eluted after 1. Next, 32% acetonitrile-0.02 Mphosphate buffer (pH 4.0), solvent B, was employed as a mobile phase. The active fractions eluted 4~5 and 7~8minutes after injection while those corresponding to 1 eluted 23~25minutes after injection. Other extracts were analyzed in the same manner showing nearly the same HPLCpattern as the bile extract as listed in Table 2 . In order to analyze the active fractions in detail, 28% acetonitrile-0.02M phosphate buffer (pH 4.0), solvent C, was used. Comparing the active fractions and the absorption peaks detected at UV214nm, the peaks for retention time 7.8 and 15.8minutes corresponded to the contractile activity. The bioactive components were designated PI and P2, respectively. The HPLCpatterns of the crude extracts from blood and liver are shown in Fig. 3 . The extracts from the liver, bile and urine contained PI and P2.
Isolation of Bioactive Metabolites A procedure for isolation ofEM574 PI (3) and P2 (4) is shown in Fig. 4 . Compound1L was administered (lOmg/kg, iv) to dogs. After 30 minutes, the dogs were killed and the livers were removed. They were homogenized in methanol and centrifuged. The supernatant was purified according to the method described above using a series of HP-20 chromatography and solvent Chromatogram; UVabs. 214nm
Histogram; contractile activity in vitro extraction at pH 8.5. The extracts was subjected to preparative HPLC(ODS) using solvent C as a mobile phase to give the fractions containing PI and P2. They were extracted with ethyl acetate at pH8.5 to afford 3 and 4, respectively. The amount of the metabolite was too small to be weighed; therefore, the weight was estimated by integration of the peak area detected at UV214nm on HPLCanalysis upon the hypothesis that both metabolites have the same UVabsorption pattern. The extracts from urine were purified by HPLCin the same mannerto afford 3 and 4, respectively.
Structures of Bioactive Metabolites The bioactive metabolites, 3 and 4, showed single peaks and the same UV spectra as 1 on three dimensional HPLC analysis. In the FAB-MS analysis, they both showed m/z 760 (MH+) and 602 (MH+-cladinose).
These data indicate that the metabolites are oxidized derivatives of 1. When the *H NMRspectra of3 and 4 were compared with that of 1, major differences were observed only in the signals corresponding to the ethyl group (C13, 14 and 15) . In the^^H COSY analysis, 3 had no 15-methyl group but had methylene protons (S 3.5-3.8ppm), which were regarded as those neighboring to <9-atom. The metabolite 4 showed a doublet The lactobionate of 2 (2L) was treated in the same manner to obtain the corresponding EM523PI (5) and EM523P2 (6) . Their structures were also elucidated by spectral analysis and found to be the 15-and 14-hydroxyl derivatives of 2, respectively, as shown in Fig. 1 . The complete assignment of 13C NMRsignals is shown the accompanyingpaper.1 5)
Preparation of the Bioactive Metabolites with Dog Liver Homogenates
The amounts of the bioactive metabolites obtained were too small to investigate the biological properties and the physico-chemical data were not sufficient to confirm the structures. Therefore, oxidation of 1 and 2 with mammalian liver homogenates was examined. In the first trial, 1 was incubated in dog liver homogenate for 1 hour, but it remained unchanged in the homogenate.
In general, enzymatic oxidation with mammalian liver homogenate requires NADPH as the co-enzyme along with enzyme, substrate and inorganic salts. Therefore, NADP and D-glucose-6-phosphate (G6P) with G6P
dehydrogenase (for NADPreduction) were employed as the in situ NADPHsupplying system.16) The liver homogenates were prepared as follows. The liver was homogenized in phosphate buffer (pH 7.4) with a Potter-Elvehjem homogenizer. The homogenate itself could be used as the enzyme fluid, but in order to avoid any contamination, the homogenate was centrifuged, and the supernatant was used for the enzymatic reaction.
In the preliminary experiment, the substrate (1L) concentration was 100 /zg/ml, and the reaction temperature was 37°C. The reaction process was monitored by HPLCanalysis to detect the remaining substrate in the reaction mixture. As the result, 84% of 1 was consumed during the first hour of the reaction. The procedure for isolation of the metabolites from dog liver was applicable to this enzymatic conversion. The reaction mixture was purified by HP-20 chromatography and preparative HPLC (ODS) to afford 3 and 4. Compounds5 and 6 were prepared in the same manner from 2. The conversion yields of PI and P2 are summarized in Table 3 . Biological Activity
The contractile activity in isolated rabbit duodenum (in vitro) and GMSactivity (in vivo) of the obtained metabolites are summarized in Table 4 .
Discussion
Here we have described the isolation, structure determination and the preparation of 15-and 14-hydroxyl AUG. 1996 derivatives of EM574 (1) and EM523 (2) as the genuine bioactive metabolites. All the metabolites showed activity comparable to that of the parent compoundin the in vitro assay. On the other hand, they exhibited 2-to 3-fold stronger GMSactivity than 1 and 2 in vivo. In the metabolic experiments, bioactive metabolites 3 and 4 were detected in the plasma after oral administration of [14C]-labeled 1 to dogs;14) therefore, the metabolites 3 and 4 are designated as M-IV and M-V, respectively.
These observations indicate that these metabolites, rather than the parent compound,are responsible for the majority of the GMSactivity. Actually, 1 is undergoing clinical trials for treatment of chronic gastritis and the metabolites M-IV and -V are detected in blood of human treated. The pharmacokinetical study of these metabolites is in progress.
Experimental
Contractile Activity Using Isolated Rabbit Duodenum
In Vitro17)
Male NewZealand white rabbits weighing about 3 kg were killed by injecting air into a vein, and the duodenum was removed. A preparation of about 2 cm was mounted along the longitudal axis in an organ bath containing 20ml of tyrode solution which was kept at 37°C and aerated continuously with a gas of 5% CO2 in oxygen. Each preparation was loaded with a tension of 1.0g, and isotonic contractions were recorded on a recorder (Recti-Horiz-8K, NECSan-ei, Japan) by means of an isotonic transducer and amplifier (ME-4012, NEC San-ei). After a stabilization period, each compound was added cumulatively to the organ bath. Test compounds were dissolved in EtOH, and lactobionic acid (1 mg/mgof test compound) was added. The resulting solution was diluted with saline. Contractions were expressed as a percentage of that induced by 10"4m acetylcholine, and the EC50 values for the test compounds were obtained.
GMS Activity In Vivo18)
Male beagle dogs weighing about 10 kg were subjected to laparotomy under pentobarbital anesthesia, and a strain gauge force transducer (F-12 IS-60, Star Medical, were used for the experiment more than 2weeksafter the operation. A lead wire of the strain gauge force transducer was connected to a recorder through an amplifier. The gastric motor activity was recorded on a polygraph (FWR3701, Graphtech, Japan). Solubilized test materials solution prepared as described above was administered intravenously 15minutes after the spontaneous interdigestive migrating contractions (IMC) in the stomach terminated. To measure the motility quantitatively, the signals from the stomach were put into a signal processor (7T18, NEC San-ei) every 100 msec. The motor index of contractions induced by the test compoundswas calculated according to the procedures described previously.18) The area of contractions induced by the test compounds was calculated and expressed as a percentage of the area assuming that the maximumcontraction of IMClasted for 1 minute. The dose inducing a contraction area of 200%was determined from dose-response curves. GMSactivity was expressed as ED200 (/ig/kg).
Measurement of Physico-chemical Data
The UVspectra were measured at 23~28°C in methanol. The FAB-MS spectra were measured on a Shimadzu 9020-DF spectrometer equipped with a FAB ion source and a computer system. The (5-values in the NMR spectra were recorded in ppmdownfield from tetramethylsilane (TMS) using a Bruker AC-300 spectrometer.
Isolation of Bioactive Metabolites from Dog Liver
Compound 1L (lOmg/ml, solution in saline) was injected intravenously into three dogs (weight, 7.08 .0kg) in a dose of lOmg/kg. After 30minutes, they were killed and exsanguinated. The livers (weight, 2002 20g, total 630g) were then immediately excised and homogenized in MeOH(2.5 liters) at ice-cooled temperature with a Potter-Elvehjem homogenizer. The homogenate was centrifuged at 8000rpm for 10minutes, and the supernatant wasconcentrated to removethe solvents. The remainder (400 ml) was adsorbed on Diaion HP-20
(20-50mesh, 100ml, Mitsubishi Chem. Ind., Japan), washed with water, 50% MeOHaq., 80% MeOHaq. (500ml each) and eluted with 80% MeOHin 5mMHC1 (400ml). The eluate was concentrated to about 10ml, adjusted to pH 8.5 and extracted with EtOAc (10ml) three times. The organic layer (30ml) was washed with water, dried over anhydrous sodiumsulfate and evaporated to give a crude powder (6.0mg). This powder was subjected to preparative HPLC(ODS; YMC-Pack AM-324, YMC,Japan, solvent C) to give fractions containing 3 and 4. These were independently concentrated to about 10ml, adjusted to pH 8. 
Isolation of Bioactive Metabolites from Dog Urine
Compound 1L (lOmg/ml, solution in saline) was injected intravenously into a dog (weight, 9.6kg) in a dose of lOmg/kg. Urine was then collected for 4hours after injection.
The urine (14.5ml) was purified with HP-20 chromatography and preparative HPLCin the same manneras described above to give powders of 3 (45Jug) and 4 (71 iug). The supernatant (1.0 liter) of the dog liver homogenate prepared as described above was dispensed in 333-ml portions into 1-liter Erlenmeyer flasks. Under ice-cooling, nicotinamide (1.0m aq., 1.5ml), MgCl2 (1.0m aq., 0.75 ml), G6P (255 mg), NADP (34 mg), G6P dehydrogenase (G6P-DH, 100unit/ml, 150/4) and 1L (lOmg/ml in water, 7.5ml) were added in turn to each of the flask and mixed gently. The flasks were stoppered with urethane plugs and shaken at 37°C for 2hours. The reaction mixtures were combined, adjusted to pH 5.4 and washed with EtOAc-hexane (2 : 1, 900ml). The aqueous layer was mixed with NaCl (100g), adjusted to pH 8.5 and extracted with EtOAc (500ml) three times. The EtOAc layers were combined, washed with 10% NaCl aq. (500ml), dried over anhydrous sodium sulfate and evaporated to give a crude syrup (204mg). This was dissolved in MeOH(1.0 ml) and subjected to preparative HPLC (YMC-Pack D-ODS-5, solvent C, flow rate 10 ml/minute) to give fractions containing 3 and 4. These were independently adjusted to pH 7.4, concentrated to about 10ml, mixed with NaCl (2.0g), adjusted to pH 8.5 and extracted with EtOAc (8ml) three times. The organic layers were washed with saline, dried over anhydrous sodium sulfate and evaporated to give powders of 3 (5.8mg) and 4 (6.2mg, total yield, 7.8%).
UV: 3, Amax 210nm (e 7600), 4, 2max 210nm (e 8000), This was treated in the same manner as described above to give a crude powder of 3 (HOmg) and a pure powder of 4 (27mg, yield 7.0%). The crude powder (HOmg) was purified by repeating preparative HPLC (D-ODS-5, mobile phase: 23%, 25% acetonitrile and 50%MeOH-0.02Mphosphate buffer; pH 4.0) to give powders of 3 (28mg, purity 85% and 30mg, purity 60%, yield of3, 13.0%).
Preparation of 5 and 6 with Dog Liver Homogenates The supernatant (400ml) of the dog liver homogenate prepared as described above was dispensed in 200-ml portions into two 1-liter Erlenmeyer flasks. Under icecooling, nicotinamide (1.0m aq., 1.0ml), MgCl2 (1.0m aq., 0.50ml), G6P (170mg), NADP (23mg), G6P-DH (100unit/ml, 100ml) and 2L (20mg/ml in water, 2.5ml) were added in turn to each flask and mixed gently. The flasks were stoppered with urethane plugs and shaken at 37°C for 2.5hours. The reaction mixtures were treated in the same manneras described above to give a crude syrup (112mg). This was dissolved in MeOH(1.3ml) and subjected to preparative HPLC(D-ODS-5, solvent C, flow rate 10 ml/minute) to give fractions containing 5 and 6. The former was adjusted to pH 7.4, concentrated to about 10ml, mixed with NaCl (2.0g), adjusted to pH 8.5 and extracted with EtOAc (8ml) three times. The organic layers were washed with saline, dried over anhydrous sodium sulfate and evaporated to give a powder of5 (2.8mg). The latter was adjusted to pH 7.4, concentrated to about 10ml, washed with EtOAchexane (2 : 1, 8ml), mixed with NaCl (2.0g), adjusted to pH 8.5 and extracted with EtOAc (8 ml) three times. The organic layers were combined, washed with saline, dried over anhydrous sodiumsulfate and evaporated to give a powder of6 (4.7mg, 5 and 6, total yield, 12.0%).
FAB-MS: 5, 6; 746 (MH+), 588 (MH+ -cladinose), AUG. 1996 IR: 5, 3430, 2970 , 2930 , 1730 , 1630 , 1450 , 1380 , 1200 , 1170 , 1050 , 1010 , 6, 3430, 2970 , 2930 , 1730 , 1640 , 1460 , 1380 , 1170 , 1050 
